


Detailed analysis of accumulated losses

Date:	17 March 2025
Name of the Listed Company:	Gulf Pharmaceutical Industries PSC
Define the period of the financial statements:	YE 2024
Value of the Accumulated losses:	AED -305.0 million as of 31 December 2024
Accumulated losses to paid-up capital ratio (%):	26.4% as of 31 December 2024
The main reasons for accumulated losses and the period in which these losses began.	The accumulated losses are carried forward from previous years, and have decreased by 41.7 mAED in 2024 driven by the total comprehensive income for the year.
Summary of the steps and initiatives undertaken by the company to address the accumulated losses:	<p>The following measures were taken:</p> <ul style="list-style-type: none"> ● Continue development of our topline in key strategic markets. ● Restructure products portfolio and launch new products in the therapeutic areas in various markets. ● Implement further process improvements and productivity enhancement initiative. ● Prudent cost containment initiatives.

The Name of the Authorized Signatory	Sheikh Saqr Humaid Al Qasimi
Designation	Chairman
Signature and Date	17 March 2025 
Company's Seal	